China biotech disclosure · Phase 3 topline · Staphylococcus aureus

Olymvax says its Staph vaccine works. The field has not seen that before.

On 11 July 2026, Chengdu Olymvax (688319.SH) disclosed that its Phase 3 trial of rFSAV, co-developed with Army Medical University, unblinded at 73.25% protective efficacy against a 60% pre-specified target in Chinese elective-surgery patients. It is a topline result that, if it holds up, would be the first pivotal-trial success anywhere in twenty years of Staphylococcus aureus vaccine development, and within a week an anonymous report challenging the numbers had wiped almost a third off the company's share price.

Sources: Chengdu Olymvax Biotech Co., Ltd., Voluntary Disclosure Announcement 2026-032, 11 July 2026 (translated by VacZine Analytics); Shanghai Stock Exchange STAR Market company filings, July-August 2026. Companion analysis to VacZine Analytics' Staphylococcus aureus (MRSA) BSI/SSI Vaccines Forecast, USA (VAMV002).

73.25%
Phase 3 protective efficacy
reported, vs. a 60% pre-specified target
0
Study-drug-related deaths
reported through day 365 of follow-up
4
Major S. aureus vaccines
that have now failed in Phase 2b/3 since 2005
-31%
Olymvax share-price move
over the 5 trading days after the data was challenged
Latest · Jul–Aug 2026

The 73.25% figure did not go unchallenged. Olymvax's 11 July filing was a voluntary disclosure, made ahead of its full clinical study report. Within two days, an anonymous report began circulating online questioning the case-count arithmetic behind the result. Olymvax's shares fell by approximately 31% over the following five trading days, including an 8% single-day drop on 17 July, the day the company issued a point-by-point rebuttal: it said the figures came from an independent third-party statistics team using standard Cox proportional-hazards methodology, filed a police report over the circulated document, and pledged to submit its complete analysis files to China's National Medical Products Administration (NMPA) for review. By late August, shares were still trading around CNY 30, roughly a third below their 52-week high of CNY 44.90, and little changed from where they closed the week the dispute broke.

Finding 01 · Why this matters

Every major Staph vaccine has failed. This is the first that has not, yet.

Staphylococcus aureus has beaten every well-resourced vaccine programme that has reached a pivotal trial in the last two decades. Nabi's StaphVAX failed its confirmatory Phase III in 2005 in haemodialysis patients, showing no reduction in infections and taking two-thirds off Nabi's share price. Merck and Intercell's V710 was terminated in 2011 after an independent data monitoring committee found it unlikely to show a statistically significant benefit in cardiothoracic surgery patients, alongside a mortality and multi-organ-dysfunction imbalance that, while not itself statistically significant, was concerning enough to stop the trial outright. Pfizer's SA4Ag, tested in elective spinal-fusion patients, failed to demonstrate efficacy and was terminated in 2018. GSK's SA5Ag, published in March 2026, came in at minus 38.1% efficacy against recurrent skin infections, worse than placebo. Set against that run of results, a company-reported 73.25% efficacy against a pre-specified 60% target, in a genuinely comparable surgical population, would be the field's first pivotal-trial success if it survives scrutiny.

2005
Nabi · StaphVAX
Confirmatory Phase III, ~3,600 haemodialysis patients. No reduction in S. aureus infections vs. placebo.
Outcome: FailedProgramme discontinued; Nabi's share price fell 67% on the announcement.
2011
Merck / Intercell · V710
Phase IIb/III, elective cardiothoracic surgery patients. Data monitoring committee cited futility plus a mortality/organ-dysfunction imbalance.
Outcome: TerminatedIndependent committee unanimously recommended stopping the trial.
2018
Pfizer · SA4Ag
Phase 2b/3 STRIVE trial, elective open posterior spinal-fusion patients. Failed to demonstrate efficacy.
Outcome: TerminatedProgramme terminated by Pfizer following the readout.
2026
GSK · SA5Ag
Recurrent skin and soft-tissue infection patients. Published Clinical Infectious Diseases, March 2026.
Outcome: FailedVaccine efficacy of minus 38.1% at 12 months – worse than placebo.
2026
Olymvax · rFSAV
Phase III, 60+ centres, elective-surgery patients, led by Beijing Jishuitan Hospital. Company-reported, not yet regulator-confirmed.
Outcome: Reported success73.25% efficacy vs. a 60% target – now publicly disputed.
One reveal This is not an apples-to-oranges comparison dressed up as a breakthrough. Pfizer's SA4Ag and Olymvax's rFSAV were both trialled in elective surgical patients – one of the few genuinely comparable head-to-head population matches in this entire twenty-year history.
Finding 02 · The technical divergence

Same idea, different ingredients: the antigens both failures shared

Olymvax's own 11 July disclosure describes rFSAV only as covering "five antigen targets" via a "multi-dimensional target complex vaccine technology," without naming them. The published preclinical literature co-authored by the Olymvax and Army Medical University team (Zeng & Zou et al.) describes an earlier version of rFSAV built from four E. coli-expressed recombinant proteins presenting five targets: a modified staphylococcal protein A (SpA5, blocking an immune-evasion mechanism), a hemolysin/IsdB fusion protein (neutralising a pore-forming toxin while blocking iron acquisition), a detoxified enterotoxin B (mSEB), and the manganese transporter MntC, formulated with a simple aluminium phosphate adjuvant. VacZine Analytics has not confirmed this is identical to the exact Phase 3 formulation, but it is the best available public technical record. What stands out against the two Western failures: neither Pfizer's SA4Ag nor GSK's SA5Ag used this combination, and both leaned on capsular polysaccharides (CP5/CP8) as core antigens – a target class that has now failed in both of the field's most advanced Western candidates.

Pfizer · Terminated 2018

SA4Ag

Antigens
Capsular polysaccharides CP5/CP8, ClfA, MntC (4-antigen)
Population
Elective spinal-fusion surgery, USA
Result
Failed to demonstrate efficacy
Leaned on capsular polysaccharide antigens
GSK · Failed 2026

SA5Ag (GSK3878858A)

Antigens
Protein A, alpha-haemolysin, CP5/CP8, ClfA (5-antigen)
Adjuvant
AS01E – a potent, proprietary system
Result
Minus 38.1% efficacy at 12 months
Potent adjuvant, still leaned on capsular polysaccharides
Olymvax · Reported 2026

rFSAV

Antigens (published record)
SpA5, hemolysin/IsdB fusion, mSEB, MntC – no capsular polysaccharides
Adjuvant
Aluminium phosphate – a simple, established adjuvant
Result
73.25% efficacy reported, disputed
Adds iron/manganese "nutritional immunity" targets instead

The other divergence is patience, not chemistry. Olymvax's clinical trial approval for rFSAV was granted by China's then drug regulator in June 2015 – roughly eleven years before this Phase 3 readout. The trial itself ran across more than 60 centres nationally, led by Beijing Jishuitan Hospital, one of China's largest orthopaedic and trauma hospitals, in partnership with Army Medical University (formerly Third Military Medical University), an institution with a long research track record in wound and hospital-acquired infection. It is a methodical, decade-plus programme rather than a fast-follower leapfrog.

One reveal GSK's SA5Ag used a considerably more potent adjuvant system (AS01E) than rFSAV's plain aluminium phosphate, and still failed. That points toward antigen selection, not adjuvant strength, as the more likely point of difference – though without the full Phase 3 dataset this remains VacZine Analytics' reading, not a confirmed mechanism.
Finding 03 · Reading the market reaction

Five reasons to treat 73.25% as provisional, not proven

VacZine Analytics cannot independently verify either Olymvax's original figure or the anonymous report that disputed it – that adjudication sits with the trial's statisticians and, in time, with NMPA. What can be assessed is the structure of the disclosure itself, and on that basis there are several concrete reasons for caution that have nothing to do with which side of the dispute turns out to be right.

Disclosure type
Voluntary, pre-CSR
Filed ahead of the full clinical study report, which Olymvax's own announcement says is still being completed.
Regulatory status
Pre-filing, China only
No registration application yet submitted; manufacturing, clinical-data and R&D site inspections all still to come.
Market reaction
-31% in 5 days
Unresolved data-integrity dispute; shares had not recovered as of late August 2026.
  • It is a topline, pre-CSR disclosure. Olymvax's own announcement states the clinical trial summary report is still being written – this is a statistics team's headline output, not the completed record.
  • No regulator has reviewed it. A registration filing requires clinical-data, manufacturing and R&D site inspections that have not yet taken place, by Olymvax's own account.
  • It is under active, public challenge. An anonymous report disputing the case-count arithmetic remains unresolved; Olymvax has rebutted it and filed a police report, but the underlying data has not been independently adjudicated.
  • The population and pathway are China-only. The trial's surgical population, standard of care and regulatory route do not automatically transfer to the US surgical and ESRD populations VacZine Analytics' own USA-focused model covers. Olymvax's risk disclosure commits only to "actively pursuing" overseas licensing – there is no confirmed FDA pathway.
  • Olymvax's own filing flags substantial commercial uncertainty, even assuming approval: physician and patient acceptance of a first-in-class vaccine, potential future competition from better antibiotics, and what the company itself calls a "relatively long" market-adoption curve.
One reveal Olymvax's shares still had not recovered by late August – trading around CNY 30, roughly a third below their 52-week high of CNY 44.90. The market, at least, is not yet treating this result as settled.
MarketVIEW · Staphylococcus aureus (MRSA) BSI/SSI Vaccines, USA · VAMV002

The full USA Staph vaccine forecast, tracking this development

This is one contested topline result inside a field with a twenty-year history of pivotal-trial failure. The live MarketVIEW model tracks the post-SA4Ag, post-SA5Ag competitor landscape – including Olymvax's rFSAV, Integrated Biotherapeutics' IBT-V02 and Eli Lilly/LimmaTech's LBT-SA7 – against scenario-based US revenue forecasts for surgical and ESRD populations.

View the Staph aureus report ← Back to homepage